Page 29 - Poster Presentation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

National University of Science and Technology goes online for its first NUTechFest 2021 By: Times News Service Muscat: National University of Science and Technology in the Sultanate of Oman is a leading player in the higher education sector and is well known for its innovative initiatives and quest for social values. This year’s NUTech Fest adds one more feather to its cap by replacing the traditional face to face techfest event with a fully online one. To those who are not aware, the NUTechFest is a technical gathering for undergraduate students across the nation with many interesting com...

/PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic...

For a better future 27 Apr 2021 / 10:16 H. Gold Award winner Eng’s project involved the anti-diabetic properties of cinnamon-fortified cheese. (above) The project by Hew on a host-originated probiotic to improve growth efficacy of red tilapia fish also won a Gold Award. SCIENTIFIC research for industrial application is at the core of Tunku Abdul Rahman University College’s (TAR UC) applied science programmes. As such, applied science students are encouraged to conduct research projects that have potential for practical use in industries. An example of such would be the research pro...

Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome News provided by Share this article Share this article WOODCLIFF LAKE, N.J., April 16, 2021 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeli...

STAFFORD, Texas--(BUSINESS WIRE)--Apr 10, 2021-- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is critical to developing dosing and booster treatment strategies that are designed to achieve and sustai...